AB0594 RELATION OF CERTAIN BLOOD PICTURE PARAMETERS AND VASCULAR ENDOTHELIAL GROWTH FACTOR TO CLINICAL MANIFESTATIONS AND DISEASE ACTIVITY IN BEHÇET'S DISEASE PATIENTS
Background: Behçet's disease (BD) is a systemic inflammatory condition sharing the clinical features of both auto-inflammatory diseases and variable vessel vasculitis. Endothelial dysfunction (ED) plays an important role in the pathogenesis of BD. Several markers can be used to evaluate ED as mean platelet volume (MPV), red cell distribution width (RDW), neutrophil-lymphocyte ratio (NLR) and vascular endothelial growth factor (VEGF). Objectives: The aim of the present study was to measure the MPV, RDW, NLR and serum level of VEGF in BD patients and to study their relation with disease manifestations and activity. Methods: Ninety six BD patients and 60 matched controls were enrolled in this study. The MPV, NLR, RDW and serum VEGF level were measured. Disease activity was assessed by the BD Current Activity Form (BDCAF). The influence of an associated metabolic syndrome (MetS) was also considered. Results: The mean age of the 96 patients was 34.9±10.1 years (18-73 years), male:female 4.7:1 and the disease duration was 9±7 years (0.6-40 years). MetS was present in 13.7%. Two patients were siblings and 5 had juvenile-onset BD. The RDW and NLR were significantly higher in patients (15.5±2% and 2.7±2.9) than controls (14.3±1.03% and 1.5±0.8) (p<0.001 each), while the MPV and VEGF were comparable. The MPV was significantly decreased in patients with vascular involvement (p=0.04) and increased in those with psychiatric disorders (p=0.02). The RDW was significantly higher in patients with vascular involvement (p=0.04) especially those with venous thrombosis and in those with neurological manifestations (p=0.03). The NLR was higher in males (p=0.01) and in those with retinal vasculitis (p=0.03) and vein occlusion (p=0.02). None of the parameters significantly correlated with the BDCAF. However, the NLR was the most valuable parameter to predict disease activity at a cut-off level of 1.69 ng/L (sensitivity 75%, specificity 55.6%). The MPV significantly correlated with the body mass index (BMI) (p=0.008), cholesterol (p=0.01) and low density lipoprotein (LDL) (p<0.001); the RDW correlated with the erythrocyte sedimentation rate (ESR) (p=0.003) and total leucocytic count (TLC) (p=0.04); the NLR with TLC (p=0.001) and blood urea (p=0.001) and VEGF with the TLC (p=0.048) and high density lipoprotein (HDL) (p=0.02). None of the parameters was significantly different according to the presence of MetS. Regarding the medications received, the RDW was significantly higher in patients who received cyclophosphamide and warfarin than those who did not (p=0.003 and p<0.001 respectively) and the level of VEGF tended to be lower in patients who received colchicine (p=0.06). Conclusions: In BD, only the RDW and NLR were significantly increased raising the possibility of a potential role in the disease susceptibility and pathogenesis with no obvious relation to the disease activity or to an associated MetS. Together with the serum VEGF, they may all serve as useful markers to reveal the pattern of organ involvement while the NLR was the most valuable cost effective parameter to signify the disease activity. Background: ANCA-associated vasculits (AAV) are a group of multi-system autoinmune diseases characterized by inflamation and necrosis in small and medium vessels.AAV could respond to diferent therapeutics protocols depends on diverse levels of clinical severity and early treatment could improve the outcome of the disease.In spite of recognized efficay of regimens consisting of cyclophosphamide and high-dose corticosteroids to control the AAV,efforts to minimize drugs-related toxicity led to consider targeted therapies. Objectives: Considering the currently quality evidence in therapies novely proposed to AAV and the severity of renal disease presentation,we suggest new rational approaches emphasizing targeting B-cells therapy and preventing disease relapse Methods: We identified the latest quality evidence using methodological search filters,assessed the evidence quality with Cochrane Renal Goup check list and determinated the strenght of recommendations by Levels of Evidence (Oxford Centre for Evidence-based Medicine) Results: Rituximab (RTX), a monoclonal anti-CD 20antibody, has emerged as the biologic agent more using in AAV patients in current publications and unlike latest Guides and Recommendations published,RTX would be recommended in induction and maintenance AAV with renal involvement treatment (Table 1) . Table 1 AAV Induction Therapy 
